Business Context and Reporting Period
Company: SeaStar Medical Holding Corp (ICU)
Filing Type: Form 8-K (Current Report)
Date of Report: January 31, 2025
Event: Entry into a Material Definitive Agreement for a registered direct offering and concurrent private placement.
Key Financial Metrics and Transaction Details
Capital Raised: The Company expects to receive aggregate gross proceeds of approximately $6.0 million before deducting estimated offering expenses.
Securities Issued:
- Common Stock: 713,000 shares issued in a registered direct offering.
- Pre-Funded Warrants: 2,816,412 warrants issued with an exercise price of $0.001 per share.
- Common Warrants: 3,529,412 warrants issued in a concurrent private placement with an exercise price of $1.70 per share.
Transaction Costs:
- Placement Agent Fee: 7.0% of aggregate gross proceeds paid in cash to H.C. Wainwright & Co.
- Placement Agent Warrants: 247,059 warrants issued to the agent with an exercise price of $2.125 per share.
Liquidity and Debt: The filing does not provide specific data on current cash balances, total debt, or liquidity ratios outside of the expected proceeds from this transaction.
Material Changes and Adjustments
Warrant Adjustments: In consideration for the new transaction, the Company agreed to voluntarily adjust the exercise price of existing Series A and Series B Common Stock Purchase Warrants (issued January 30, 2024) to $1.70 per share.
Term Extension: The term of the Series B Warrants was extended to January 30, 2029, subject to stockholder approval.
Stockholder Approval Requirement: The Company must hold a special meeting of stockholders within 120 days of the closing to approve the exercise of the Common Warrants and the issuance of underlying shares.
Outlook, Risks, and Management Commentary
Management Commentary: The offering was conducted without an underwriter or placement agent for the primary transaction, though a fee was paid to H.C. Wainwright & Co. The transaction utilizes a shelf registration statement (Form S-3) declared effective on December 22, 2023.
Risks and Contingencies:
- Dilution: The issuance of significant numbers of shares and warrants (including pre-funded warrants) will result in dilution to existing shareholders.
- Approval Risk: The ability to fully realize the capital from the Common Warrants is contingent upon stockholder approval within 120 days.
- Unregistered Securities: The Common Warrants are being offered pursuant to Section 4(a)(2) and Rule 506(b) exemptions and are not registered under the Securities Act of 1933.
Unusual Items: The filing does not disclose any unusual items, restatements, or legal contingencies beyond the standard terms of the securities offering.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received versus the estimated $6.0 million.
- Confirm the date and outcome of the special stockholder meeting required to approve the Common Warrants.
- Review the definitive Securities Purchase Agreement (Exhibit 10.1) for specific redemption rights or anti-dilution provisions not summarized in the 8-K.
- Assess the impact of the 7.0% placement fee and warrant issuance on the net capital available for operations.
- Monitor the adjusted exercise price ($1.70) of the existing Series A and Series B warrants and its impact on future dilution.